Terms: = Prostate cancer AND BCL2, Bcl-2, 596, ENSG00000171791 AND Prognosis
96 results:
1. Pretargeted radiotherapy and synergistic treatment of metastatic, castration-resistant prostate cancer using cross-linked, PSMA-targeted lipoic acid nanoparticles.
Dai L; Zhang X; Zhou S; Li J; Pan L; Liao C; Wang Z; Chen Y; Shen G; Li L; Tian R; Sun H; Liu Z; Zhang S; Wu H
J Mater Chem B; 2024 Feb; 12(9):2324-2333. PubMed ID: 38324337
[TBL] [Abstract] [Full Text] [Related]
2. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
3. Vitamin K: New insights related to senescence and cancer metastasis.
Chen A; Li J; Shen N; Huang H; Hang Q
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189057. PubMed ID: 38158025
[TBL] [Abstract] [Full Text] [Related]
4. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
5. Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A; Gusterson B; Tovey H; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley D; Hall E; Somaiah N
EBioMedicine; 2023 Feb; 88():104436. PubMed ID: 36708693
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA UBE2R2-AS1, as prognostic marker, promotes cell proliferation and EMT in prostate cancer.
Wang F; Zhao M; Jiang Y; Xia S; Sun D; Zhou D; Dong Z
Histol Histopathol; 2023 Jun; 38(6):637-645. PubMed ID: 35916204
[TBL] [Abstract] [Full Text] [Related]
7. Polymorphic variants of the CASP3, CASP9, bcl-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.
de Souza MR; de Souza MF; de Nóbrega M; Cilião HL; Dos Reis MB; Fuganti PE; Cólus IMS
Mol Biol Rep; 2022 Sep; 49(9):9079-9087. PubMed ID: 35708863
[TBL] [Abstract] [Full Text] [Related]
8. Mannose inhibits the growth of prostate cancer through a mitochondrial mechanism.
Deng YL; Liu R; Cai ZD; Han ZD; Feng YF; Cai SH; Chen QB; Zhu JG; Zhong WD
Asian J Androl; 2022; 24(5):540-548. PubMed ID: 35142655
[TBL] [Abstract] [Full Text] [Related]
9. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract] [Full Text] [Related]
10. Role of ZEB Family Members in Proliferation, Metastasis, and Chemoresistance of prostate cancer Cells: Revealing Signaling Networks.
Soleymani L; Zarrabi A; Hashemi F; Hashemi F; Zabolian A; Banihashemi SM; Moghadam SS; Hushmandi K; Samarghandian S; Ashrafizadeh M; Khan H
Curr Cancer Drug Targets; 2021; 21(9):749-767. PubMed ID: 34077345
[TBL] [Abstract] [Full Text] [Related]
11. The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer.
Matos B; Howl J; Jerónimo C; Fardilha M
Pharmacol Res; 2020 Nov; 161():105145. PubMed ID: 32814172
[TBL] [Abstract] [Full Text] [Related]
12. Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression.
Jang YG; Ko EB; Choi KC
J Nutr Biochem; 2020 Oct; 84():108444. PubMed ID: 32615369
[TBL] [Abstract] [Full Text] [Related]
13. Long noncoding RNA SNHG14 promotes malignancy of prostate cancer by regulating with miR-5590-3p/YY1 axis.
Luo ZF; Peng Y; Liu FH; Ma JS; Hu G; Lai SL; Lin H; Chen JJ; Zou GM; Yan Q; Sui WG
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4697-4709. PubMed ID: 32432733
[TBL] [Abstract] [Full Text] [Related]
14. Mechanism of Anti-cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent prostate cancer.
Abd Wahab NA; Lajis NH; Abas F; Othman I; Naidu R
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32131560
[TBL] [Abstract] [Full Text] [Related]
15. Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Sahin TK; Aktepe OH; Uckun FM; Yalcin S
Anticancer Drugs; 2020 Jul; 31(6):609-616. PubMed ID: 32044796
[TBL] [Abstract] [Full Text] [Related]
16. Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4.
Kim S; Ko D; Lee Y; Jang S; Lee Y; Lee IY; Kim S
Sci Rep; 2019 Jul; 9(1):10003. PubMed ID: 31292507
[TBL] [Abstract] [Full Text] [Related]
17. Buforin IIb induces androgen-independent prostate cancer cells apoptosis though p53 pathway in vitro.
Han Y; Lu M; Zhou J
Toxicon; 2019 Oct; 168():16-21. PubMed ID: 31229626
[TBL] [Abstract] [Full Text] [Related]
18. The preoperative neutrophil-to-lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy.
Cao Z; Ji J; Zhang C; Wang F; Xu H; Yu Y; Sun Y
Cancer Med; 2019 Mar; 8(3):1004-1012. PubMed ID: 30693666
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression.
Linder A; Hagberg Thulin M; Damber JE; Welén K
Sci Rep; 2018 Nov; 8(1):17259. PubMed ID: 30467386
[TBL] [Abstract] [Full Text] [Related]
20. Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.
Leighton X; Bera A; Eidelman O; Bubendorf L; Zellweger T; Banerjee J; Gelmann EP; Pollard HB; Srivastava M
PLoS One; 2018; 13(10):e0205837. PubMed ID: 30321230
[TBL] [Abstract] [Full Text] [Related]
[Next]
